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Introduction
It is the strong impression of Swiss experts in rheu-
matology and cardiology that current guidelines, in 
particular the recent EULAR guidelines [1], are not 
sufficiently adhered to by specialists and primary 
care physicians in Switzerland, most likely due to 
their complexity. Therefore, a Swiss expert group 
consisting of cardiologists and rheumatologists 
 elaborated user-optimised consensus recommenda-
1 This is also applicable 
for other chronic 
inflammatory diseases 
such as SLE, ankylosing 
spondylitis, and psoriatic 
arthritis.
Summary
Cardiovascular diseases (CVD) and complications occur prematurely and 
approximately 1.5 times more frequently in patients with rheumatoid 
 arthritis (RA) compared to the general population. The higher level of CV 
complications is insufficiently explained by the traditional cardiovascular 
(CV) risk factors. There is substantial evidence that chronic systemic in-
flammation contributes to excess CVD in RA and that effective suppres-
sion of RA-associated inflammation reduces CV morbidity.
CV risk assessment and management tools were developed many years 
ago for the general population. A Swiss expert group consisting of cardio-
logists and rheumatologists has elaborated the following pragmatic guide-
lines for the management of CV risk in patients with RA. In addition to sys-
tematic screening for and reduction of traditional individual CV risk factors 
based on the national risk score model, the direct link between 
 inflammation and the development of atherosclerosis demands early and 
effective control of joint and systemic inflammation. Antirheumatic ther-
apy preferably includes methotrexate, a disease modifying antirheumatic 
drug (DMARD) and, if necessary, tumour necrosis factor-α blockers or 
other biologics, because they are not only effective in the treatment of RA 
but might also reduce excess CV events in patients with RA.
Additional treatment should be initiated according to the strategies for 
lowering circulating lipids and blood pressure as published by the Euro-
pean Society of Cardiology and European Atherosclerosis Society. Phar-
macological interventions should be complemented by lifestyle changes.
Key words: cardiovascular risk; rheumatoid arthritis; disease modifying antirheumatic drug; DMARD
tions on cardiovascular (CV) risk management in pa-
tients with rheumatoid arthritis (RA) to address the 
underappreciated problem of elevated CV risk in RA 
patients. The ad-hoc expert group convened to dis-
cuss and formulate evidence-based consensus opin-
ions without systematic processing of the literature. 
The aim was to present current “best practice” to pri-
mary care physicians and rheumatologists.
Rheumatoid arthritis and risk  
for  cardiovascular disease
Patients with rheumatoid arthritis (RA) have a 50% in-
creased risk for cardiovascular diseases and their compli-
cations as compared to the general population.
RA is a chronic inflammatory joint disease of 
unknown aetiology affecting approximately 1% of 
the general population [2, 3]. As compared to the gen-
eral population, it is associated with an approxi-
mately 50% increase in CV morbidity and mortality, 
predominantly resulting from accelerated coronary 
and cerebrovascular atherosclerosis [4, 5, 6, 7].
1
 It has 
been demonstrated that the prevalence of cardiovas-
cular disease (CVD) in RA patients is increased to 
an extent comparable to type 2 diabetes mellitus 
(fig. 1) [8].
The increased incidence of CVD cannot be explained 
by traditional CV risk factors alone [9, 10]. Various 
disease-related mechanisms may contribute to pre-
mature vascular damage, including an increased 
synthesis of pro-inflammatory mediators (cytokines, 
chemokines and adhesion molecules), autoantibod-
ies against endothelial cell components or anti-apoA1 
lipoprotein, perturbations in T-cell subsets, genetic 
polymorphisms, hyperhomocysteinaemia, oxidative 
stress, abnormal vascular repair, and iatrogenic fac-
tors [11, 12]. Particularly, the systemic inflammation 
seems to account for the excess CV risk [13]. There is 
strong evidence that chronic inflammatory markers 
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are independently associated with CV mortality and 
morbidity in RA patients [14, 15, 16]. Immune dysreg-
ulation may also play a role [17]. Moreover, the 
 prevalence of CV risk factors such as dyslipidaemia, 
 diabetes, hypertension, higher Body Mass Index, or 
impaired physical fitness may be increased in RA 
 patients [18, 19]. Tobacco smoking is associated with 
both CVD and the development of RA, in particular in 
genetically susceptible individuals [20].
Although newer disease modifying antirheumatic 
drugs (DMARDs) and biologic agents have substan-
tially advanced the management of RA and other 
forms of inflammatory arthritis in the past few 
years, CVD morbidity and mortality remain signifi-
cantly increased in patients with RA [21, 22, 23]. But 
the lack of CV risk assessment tools and evidence-
based recommendations developed specifically for 
RA patients has impeded the implementation of this 
knowledge in the delivery of clinical care.
Treatment goals
Complete clinical remission is the primary treatment 
goal in the management of RA using early and effective 
antirheumatic treatment.
There is broad consensus among experts that an ade-
quate control of disease activity is a prerequisite to 
lower the CV risk in RA patients. Long-term clinical 
remission has become a realistic treatment goal in 
many patients due to new drug treatment strategies 
that improve clinical and radiographic outcomes [1, 
24]. The current standard for measuring disease ac-
tivity is the EULAR Disease Activity Score (DAS) and 
its modified version, the DAS28, including 28 joints 
[25]. The score is calculated using a formula that 
incorporates counts of tender and swollen joints (28 
joints maximum), an evaluation of the general health 
by the patient (Visual Analogue Scale 0 to 100), and 
the erythrocyte sedimentation rate or the C-reactive 
protein as systemic inflammation markers. Although 
various definitions of remission have been proposed 
during the last decade, the most widely used defini-
tion in randomised controlled trials has been a 
DAS28 index with a cut point of <2.6 [26]. 
Treatments currently used in the management of 
chronic inflammatory disorders may affect CV risk. 
Table 1 gives an overview of the current pharmaco-
therapy with information regarding CV risks associ-
ated with each drug class.
Figure 1: Prevalence of cardiovascular disease. The prevalence of cardiovascular  
disease in RA patients is comparable to patients with type 2 diabetes mellitus. From: 
Peters MJ, et al. Does rheumatoid arthritis equal diabetes mellitus as an independent 
risk factor for cardiovascular disease? A prospective study. Arthritis Rheum. 
2009;61(11):1571–9. Reprinted with permission. 
Table 1: Current pharmacotherapy of RA. Effect of different treatment options on cardiovascular risk in RA patients and source 
of clinical evidence. 
Drug class Effect on CV outcomes in RA patients Clinical evidence (References)
NSAIDs/COXIBs ←→ ? on CVD mortality or HF events prospective cohort [57, 63]
Glucocorticoids
↑ high dose  ↓ (low dose) CVD events
cross-sectional [4], prospective cohorts [58, 59],
systematic review [60], case-control [71]
Methotrexate (MTX) ↓ CVD events cross-sectional [4], prospective cohorts [62, 67], 
case-control [62], systematic review [64]
Leflunomide ↓ CVD events cross-sectional [4], prospective cohort [67]
Tumor necrosis factor-α blocking 
agents (TNF-α blockers)
↓ CVD events cross-sectional [4], prospective cohort [70, 72], 
meta-analysis [73] and systematic review [74]
Other biological agents ?
CV = cardiovascular; CVD = cardiovascular disease; HF = heart failure
1.00
0.95
0.90
0.85
0.80
0.00 1.00 3.00 3.00
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Cardiovascular risk assessment  
and estimation of risk in the general 
population and RA patients
A systematic CV risk-factor screening must be performed 
in RA patients using the risk score model presented by the 
Swiss Society of Cardiology (SGK/SSC) and the working 
group on lipids and atherosclerosis (AGLA) in 2012 (www.
agla.ch).
In RA patients, the derived CV risk estimate should sub-
sequently be multiplied by a factor of 1.5, without any re-
strictions. For this purpose the risk score chart used in 
Switzerland was modified accordingly (fig. 2). It allows 
simple and direct assessment of risk score for RA pa-
tients.
Assessment of cardiovascular risk should be performed 
annually in every RA patient.
The major traditional risk factors for CVD are tobacco 
smoking, elevated blood pressure, elevated serum to-
tal cholesterol (TC) and low-density lipoprotein cho-
lesterol (LDLC), low serum high-density lipoprotein 
cholesterol (HDL-C), diabetes mellitus, and advanc-
ing age. The quantitative relationship between these 
risk factors and coronary heart disease (CHD) risk has 
been elucidated by the Framingham Heart Study and 
other studies [27, 28]. These show that the major risk 
factors are additive in predictive power. Accordingly, 
the total risk of a person can be estimated by a sum-
mation of the risks imparted by each individual ma-
jor risk factor. The risk for CHD is assessed with risk 
charts, and usually the predicted 10-year risk of fatal 
Figure 2: SCORE – European Low Risk Chart for Rheumatoid Arthritis Patients. From (fig. 2A modified by the authors of this manuscript): Perk J, et al.  
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J. 2012;33(13):1635–701. Reprinted with  
permission.  
A
B
 
15% and over
10%–14%
5%–9%
3%–4%
2%
1%
<1%
10-year risk of fatal 
CVD in populations  
at high CVD risk
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CHD is calculated. The European risk prediction sys-
tem SCORE (Systemic COronary Risk Evaluation) has 
been developed to define the lifestyle, risk factor, and 
therapeutic targets for CVD prevention. SCORE is rep-
resentative of typical European populations, and the 
risk score system has been optimised for coronary 
prevention in European clinical practice.
All risk score charts are presented for TC. However, 
new data show that HDL-C can substantially contrib-
ute to risk estimation if entered as a separate variable 
as opposed to the TC/HDL-C ratio [29, 30]. For exam-
ple, HDL-C modifies risk at all levels of risk as esti-
mated from the SCORE cholesterol charts. Therefore, 
a new risk score chart was developed that includes 
HDL-C.
The Swiss national guidelines for the prevention of 
CV events were published in 2005 by the Swiss Soci-
ety of Cardiology (SGK/SSC) and the working group 
on lipids and atherosclerosis (AGLA) [31]. In these 
guidelines, CV risk is stratified into low (<10%), inter-
mediate (10–20%) and high (>20%). Primary preven-
tion with statins and/or antihypertensive agents is 
only indicated in the general population when this 
10-year risk is above 10% (fig. 2). 
It is very likely that the use of available CV risk score 
charts underestimates the CV risk in RA patients, since 
only traditional risk factors are considered. Nontradi-
tional risk factors such as disease severity and duration 
significantly increase the CV risk in patients with RA [32, 
33, 34]. However, other factors such as rheumatoid factor 
(RF), anti-cyclic citrullinated peptide antibodies (anti-
CCP) positivity are also relevant [35, 36]. Therefore, EU-
LAR evidence-based recommendations introduce a 
multiplication factor 1.5 to adapt the risk score models 
for RA patients, provided that 2 of the following 3 crite-
ria are fulfilled: Disease duration of over 10 years, RF or 
anti-CCP positivity, presence of certain extra-articular 
manifestations [1]. Our Swiss expert group proposes to 
extend this recommendation to all RA patients in order 
to simplify management strategy and to acknowledge 
the fact that most of the epidemiological studies on the 
risk of CVD in RA did not stratify the patients according 
to these criteria. In addition to RA, this approach should 
be implemented in patients with other forms of inflam-
matory arthritis such as psoriatic arthritis and ankylos-
ing spondylitis, and autoimmune diseases such as sys-
temic lupus erythematosus.
Intervention strategies on the basis  
of the cardiovascular risk profile
The same intervention strategies for lowering of LDL-C in 
the normal population with elevated CV risk should be 
used in RA patients.
Table 2: Intervention strategies for lowering LDL-C levels in patients with RA. For lowering LDL-C levels in RA patients the same 
strategies as in the normal population with elevated cardiovascular risk should be used. (Reprinted from: Perk J et al. European 
Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J 2012;33:1635–1701, with 
permission )
Total CV risk 
(SCORE) %
LDL-C levels
<70 mg/dl 
<1.8 mmol/l
70 tp <100 mg/dl 
1.8 to <2.5 mmol/l
100 to <155 mg/dl 
2.5 to <4.0 mmol/l
155 to <190 mg/dl 
4.0 to <4.9 mmol/l
<190 mg/dl 
<4.9 mmol/l
<1 No lipid 
 intervention
No lipid 
 intervention
Lifestyle  
intervention
Lifestyle  
intervention
Lifestyle interven-
tion, consider drug  
if uncontrolled
Class
a
/Level
b
I/C I/C I/C I/C IIa/A
≥1 to <5 Lifestyle 
 intervention
Lifestyle 
 intervention
Lifestyle 
interven tion, 
consider drug if 
 uncontrolled
Lifestyle intervention, 
consider drug if 
 uncontrolled
Lifestyle interven-
tion, consider drug  
if uncontrolled
Class
a
/Level
b
I/C I/C IIa/A IIa/A I/A
>5 to <10,  
or high risk
Lifestyle inter-
vention, consider 
drug*
Lifestyle 
 intervention, 
 consider drug*
Lifestyle inter-
vention and im-
mediate drug 
intervention
Lifestyle intervention 
and immediate drug 
intervention
Lifestyle interven-
tion and immediate 
drug intervention
Class
a
/Level
b
IIa/A IIa/A IIa/A I/A I/A
≥10 or very  
high risk
Lifestyle inter-
vention, consider 
drug*
Lifestyle interven-
tion and immedi-
ate drug interven-
tion
Lifestyle inter-
vention and im-
mediate drug 
intervention
Lifestyle intervention 
and immediate drug 
intervention
Lifestyle interven-
tion and immediate 
drug intervention
Class
a
/Level
b
IIa/A IIa/A I/A I/A I/A
* In patients with MI, statin therapy should be considered inexpective of LDL-C levels. 
a
 Class of recommendation.
b
 Level of evidence. References to level A: 15–41. 
CV = cardiovascular; LDL-C = low-density lipoprotein-cholesterol; MI = myocardial infarction
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The LDL-C goals are derived from the total CV risk score, 
as proposed by ESC/EAS in their guidelines for the man-
agement of dyslipidaemia in 2011 (see table 2).
The management of arterial hypertension in RA patients is 
based on the levels of systolic and diastolic blood pressure 
and the CV risk as described in the ESH/ESC guidelines in 
2013. The antihypertensive treatment should be initiated 
according to the recommendations in table 3, which was 
modified by the expert group from the corresponding table 
in the ESH/ESC guidelines for specific use in RA patients.
It is well-established that low levels of HDL-C and 
high levels of TC, LDL-C and TG are associated with an 
increased risk for CV events in the general popula-
tion. In particular, the TC/HDL-C ratio is an impor-
tant prognostic factor for future CV events [37, 38]. In-
tervention trials have demonstrated that cholesterol 
modification, especially reduction in LDL-C levels is 
associated with favourable effects on the CV event 
rate, including CV mortality, especially in patients at 
high risk [39, 40, 41, 42]. Unfortunately, so far there 
are no data from intervention trials on the effect of 
LDL-C lowering pharmacotherapy CV event rate in 
patients with RA. On the other hand, there is no indi-
cation that lipid lowering pharmacotherapy is less ef-
ficacious in RA patients.
RA patients with active disease often have low HDL-C 
levels, high triglyceride levels and unfavourable TC/
HDL-C ratio [43, 44]. It appears that DMARDs have 
beneficial effects on the lipid profile in patients with 
early active RA [45, 46, 47, 48]. However, the data are 
conflicting. 
Experts from the European Society of Cardiology 
(ESC) and the European Atherosclerosis Society (EAS) 
have developed new guidelines for the management 
of dyslipidaemia in 2011 [49]. In these guidelines, the 
SCORE system has been used to categorise patients as 
very high, high, moderate or low CV risk, as a basis 
for treatment decisions.
LDL-C remains the primary priority in lipid manage-
ment. In patients at very high risk (as derived from 
the SCORE tables), the LDL-C goal is set at <1.8 mmol/l 
(<70 mg/dl) and/or at least a 50% reduction in LDL-C if 
the target cannot be reached. In patients at high risk 
(e.g., marked elevation of only one risk factor), the 
LDL-C goal is <2.5 mmol/l (<100 mg/dl); in patients 
with moderate risk, LDL-C should be lowered to <3 
mmol/l (<115 mg/dl) (table 2).
Hypertension should be considered a major risk fac-
tor for an array of CV and related diseases [50, 51]. 
Randomised placebo-controlled trials on blood pres-
sure lowering have demonstrated that antihyperten-
sive treatment translates into significant reductions 
of CV morbidity and mortality [52].
In 2013, ESH/ESC issued new guidelines on the manage-
ment of hypertension [53]. Blood pressure is catego-
rised as optimal (systolic blood pressure [SBP] less than 
120 mm Hg and diastolic blood pressure [DBP] less than 
80 mm Hg), normal (SBP 120–129 mm Hg and/or DBP 
80–84 mm Hg), and high-normal (SBP 130–139 mm Hg 
and/or DBP 85–89 mm Hg), followed by 3 grades of hy-
pertension, and a separate category for isolated sys-
tolic hypertension, The presence of RA should be con-
sidered as a distinct CV risk factor as presented in the 
modified table of the expert group (table 3). 
According to the new ESH/ESC guidelines, initiation 
of blood pressure lowering therapy should be based 
on two criteria, i.e., the level of systolic and diastolic 
pressure (SBP/DBP) and the CV risk. The goal of treat-
Table 3: Antihypertensive treatment strategies in RA patients. (Modified from Mancia G, et al., Eur Heart J. 2007;28:1462–536, 
with permission.)
Blood pressure (mm Hg)
Other risk factors 
OD or disease
Normal 
SBP 120–129 
or 
DBP 80–84
High normal 
SBP 130–139 
or 
DBP 85–89
Grade 1 HT 
SBP 140–159 
or DBP 90–99
Grade 2 HT 
SBP 160–179 
or 
DBP 100–109
Grade 3 HT 
SBP ≥180 
or 
DBP ≥110
RA patients  
±1 other risk  
factor
Lifestyle changes Lifestyle changes
Lifestyle changes 
for several weeks  
then drug treatment 
if BP uncontrolled
Lifestyle changes 
for several weeks  
then drug treatment 
if BP uncontrolled
Lifestyle changes 
+ 
immediate drug 
treatment
RA patients  
≥2 other risk 
factor
Lifestyle changes
Lifestyle changes 
and consider drug 
treatment
Lifestyle changes 
+ 
Drug treatment
Lifestyle changes 
+ 
Drug treatment
Lifestyle changes 
+ 
Immediate drug 
treatment
Diabetes Lifestyle changes
Lifestyle changes + 
Drug treatment
Established CV  
or renal disease
Lifestyle changes 
+ 
Immediate drug 
treatment
Lifestyle changes 
+ 
Immediate drug 
treatment
Lifestyle changes 
+ 
Immediate drug 
treatment
Lifestyle changes 
+ 
Immediate drug 
treatment
Lifestyle changes 
+ 
Immediate drug 
treatment
HT, hypertension; OD subclinical organ damage; SBP, systolic blood pressure; DBP, diastolic blood pressure
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ment is to reduce blood pressure to at least below 
140/90 mm Hg (SBP/DBP).
Non-pharmacological interventions
Lifestyle changes should be recommended individually 
according to the presumed effectiveness and feasibility. 
Smoking cessation is of paramount interest.
The new ESC/EAS guidelines for the management of 
dyslipidaemia issued in 2011 stress that lifestyle in-
terventions, including smoking cessation, healthy 
diet, moderate exercise and moderate alcohol con-
sumption, should be the first step for managing lip-
ids in all patients [49]. Moderate-intensity physical 
activity is significantly lower in RA patients com-
pared with matched controls [54], and potentially 
amenable to change. To decrease LDL-C and TC, re-
duction in dietary saturated fat and trans-fat, as 
well as cholesterol itself is necessary. Dietary fibre 
consumption should be increased. It is also recom-
mended to use food enriched with phytosterols. Fi-
nally, the guidelines focus on the considerable im-
portance of body weight and central obesity, as they 
are one of the main problems in western countries.
Pharmacological interventions
Control of the joint disease remains the principal aim, 
but not all drugs have this far demonstrated additional 
CV benefits in this population, an element to take into 
consideration whenever possible, in particular in the 
high CV risk patient.
Current RA therapy strategies aim at remission with 
full control of joint and systemic inflammation, a 
control of the inflammation which is an integral part 
of the strategy to lower the cardiovascular risk, as 
suggested in the guidelines of ESC/EAS (2012), EULAR 
(2010) and ESH/ESC (2013). Classical nonsteroidal anti-
inflammatory drugs (NSAIDs) and cyclooxygenase-2 
inhibitors (COXIBs) are very commonly used in the 
treatment of RA. There is still controversy about the 
effects of NSAIDs on CV disease and mortality. Ac-
cording to the findings of a meta-analysis, high dose 
regimens of ibuprofen and diclofenac are associated 
with an increased risk of CV events, but high doses of 
naproxen are not associated with such an excess [55]. 
In another cohort study, this risk appeared to be me-
diated mainly by the effect of NSAIDs on blood pres-
sure [56] stressing the importance of BP control. Of 
note, the anti-inflammatory effect of NSAIDs could 
potentially counteract this risk, as in a cohort study 
in RA patients, the use of NSAIDs was not associated 
with excess CVD or mortality from all causes [57].
Corticosteroids are commonly used in rheumatic pa-
tients and may influence the CV risk in two compet-
ing ways. On one hand their anti-inflammatory and 
antiproliferative action on vessel walls may be car-
dio protective, and on the other they affect blood 
pressure, insulin resistance, lipid profiles, body 
weight, platelet activity and fat distribution, espe-
cially when used long-term at high doses [58, 59]. 
High-dose corticosteroid therapy appears to be asso-
ciated with a dose-dependent CV risk increase in RA 
patients, while exposure to low doses of corticoste-
roids for 1–3 years does not [57, 60].
There are several indications that DMARDs can alter 
CV risk by influencing atherosclerotic processes di-
rectly through suppression of inflammation or indi-
rectly by affecting CV risk factors. However, few stud-
ies have investigated their effects on the occurrence 
of CVD in RA patients. 
Methotrexate (MTX) is a cornerstone of the treat-
ment of RA. It improves the clinical signs of disease 
activity and slows radiographic progression. Patients 
with RA who take MTX have lower mortality rates 
and decreased CV morbidity [4, 61, 62]. In a large co-
hort study of RA patients MTX was associated with a 
significant decrease in the rate of acute myocardial 
infarction [63]. A recent meta-analysis came to the 
conclusion that MTX use is associated with a reduced 
risk of CVD events in patients with RA [64].
The sparse available data on leflunomide suggest 
that, despite the small percentage of RA patients de-
veloping hypertension under leflunomide, it may re-
duce the risk of myocardial infarction, but the results 
are controversial [4, 65, 66, 67].
Tumour necrosis factor-α blocking agents (TNF-α 
blockers) are potent inhibitors of inflammation and 
radiographic progression in RA patients. According 
to the current Swiss and EULAR RA treatment recom-
mendations, TNF-α blockers should be favoured as 
first-line biologics [68, 69]. Their role in the preven-
tion of CV events in RA patients is of great interest, a 
further argument currently favouring their use. Sev-
eral studies indicate that TNF inhibition might im-
prove endothelial function and be associated with 
decreased CV morbidity, especially in patients with 
clinical response to therapy [4, 70, 71, 72]. Two recent 
meta-analyses support the hypothesis that treat-
ment with anti-TNF agents is associated with a re-
duced risk of all CV events, myocardial infarction, 
and cerebrovascular accidents in RA patients [73, 74]. 
The effects of other biologic agents, including abata-
cept, rituximab and tocilizumab, on CV morbidity in 
RA remain to be determined [75].
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Cardiovascular therapy
Drug treatment of dyslipidaemia and arterial hyperten-
sion is identical to that of patients without RA. Preferred 
first-line treatments are statins, ACE-inhibitors and an-
gio tensin receptor blockers.
Anti-platelet therapy is only recommended in RA pa-
tients with established CV disease.
The ESC/EAS guidelines (2011) and the EULAR evi-
dence-based recommendations (2010) propose that if 
lipid targets are not met with lifestyle changes alone, 
statins are the treatment of choice for lowering LDL 
cholesterol levels [1, 49]. The effects of statins in pa-
tients with RA might be of additional benefit, since 
they possess potential anti-inflammatory properties. 
The selection of a specific statin should be based on 
consideration of the extent of LDL cholesterol lower-
ing required and the individual’s CV risk. The Trial of 
Atorvastatin in Rheumatoid Arthritis (TARA) ran-
domised 116 patients with RA in a double-blind pla-
cebo-controlled trial to receive 40 mg of atorvastatin 
or placebo as an adjunct to existing DMARDs [76]. 
The authors found that statins mediated modest but 
clinically apparent anti-inflammatory effects with 
lowering of CRP after six months. This study provides 
some evidence to use statins to selected RA patients. 
However, it needs confirmation in a larger popula-
tion of RA patients with assessment of systemic in-
flammation, morbidity, longer follow-up, CV risk fac-
tors outcome (major cardiovascular events). Cost 
effectiveness and quality of life issues also need to be 
taken into account. Combination therapy with a cho-
lesterol absorption inhibitor (ezetimibe) or nicotinic 
acid (niacin) may be considered if the LDL-C target is 
not met.
Five classes of drugs are considered appropriate as 
first-line agents for the treatment of hypertension: 
diuretics; angiotensin-converting enzyme (ACE) in-
hibitors; calcium channel blockers (CCBs); angioten-
sin receptor blockers (ARBs), and beta-blockers. How-
ever, the use of beta-blockers in hypertension 
remains controversial.
The EULAR consensus guidelines recommend the 
preferential use of ACE-inhibitors and ARBs because 
of their favourable effect on inflammatory markers 
and endothelial function in patients with RA [77, 78].
Anti-platelet therapy is recommended for patients 
with established CV disease [79]. For patients with in-
creased CV risk the benefit is lower [80]. The benefit 
of anti-platelet therapy in RA patients is therefore 
doubtful, and has to be weighted with the increased 
risk of gastro-intestinal events in patients with con-
comitant NSAIDs.
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